Cited by 157Pharmacogenetics and Drug MetabolismNutrition, Genetics, and DiseaseComputational Drug Discovery Methods

The DOI matches its Crossref record, with a small difference in title or year; 195 of the 196 references it cites were found in a registry or an index.

Omics and Drug Response

Meyer, Urs A., Zanger, Ulrich M., Schwab, Matthias·2013·Annual Review of Pharmacology and Toxicology

DOI 10.1146/annurev-pharmtox-010510-100502

Open this paper in CoChat — free account

Abstract

A new generation of technologies commonly named omics permits assessment of the entirety of the components of biological systems and produces an explosion of data and a major shift in our concepts of disease. These technologies will likely shape the future of health care. One aspect of these advances is that the data generated document the uniqueness of each human being in regard to disease risk and treatment response. These developments have reemphasized the concept of personalized medicine. Here we review the impact of omics technologies on one key aspect of personalized medicine: the individual drug response. We describe how knowledge of different omics may affect treatment decisions, namely drug choice and drug dose, and how it can be used to improve clinical outcomes.

Integrity signals

Registry

Crossref · 10.1146/annurev-pharmtox-010510-100502

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G. N., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 307
Retracted
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
Alternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Epigenetics in Cancer
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,767
Epigenetic differences arise during the lifetime of monozygotic twins
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500398102 · Cited by 3,602
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J. V., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,533
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C. A., SCOTT, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,236
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Integrating common and rare genetic variation in diverse human populations
The International HapMap 3 Consortium (2010) · Nature · doi:10.1038/nature09298 · Cited by 3,026
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Five Years of GWAS Discovery
Visscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.029 · Cited by 2,425
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
RNA sequencing: advances, challenges and opportunities
Ozsolak, F., & Milos, P. M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2934 · Cited by 2,135
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Metabonomics
Nicholson, J. K., & Lindon, J. C. (2008) · Nature · doi:10.1038/4551054a · Cited by 1,931
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
Yeoh, A. E. J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D. H., Mahfouz, R. A., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A. R., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,914
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S. A., Phillips, E. J., Carosi, G., Molina, J., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugină, S., Козырев, О. А., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,834
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M. V., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M. F., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,829
Emergency hospitalizations for adverse drug events in older Americans.
Budnitz, D., Lovegrove, M., Shehab, N., & Richards, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1103053 · Cited by 1,748
Drug—target network
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-Ĺ., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,744
Mining electronic health records: towards better research applications and clinical care
Jensen, P. B., Jensen, L. J., & Brunak, S. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3208 · Cited by 1,680
MicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
The International Warfarin Pharmacogenetics Consortium (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,573
The mystery of missing heritability: Genetic interactions create phantom heritability
Zuk, O., Hechter, E., Sunyaev, S. R., & Lander, E. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119675109 · Cited by 1,542
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
Genomewide Association Studies and Assessment of the Risk of Disease
Manolio, T. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905980 · Cited by 1,512
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,504
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,391
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Phenomics: the next challenge
Houle, D., Govindaraju, D. R., & Omholt, S. W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2897 · Cited by 1,319
Personal omics profiling reveals dynamic molecular and medical phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y. K., Chen, R., Miriami, E., Karczewski, K. J., Hariharan, M., Dewey, F. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.009 · Cited by 1,291
Epigenome-wide association studies for common human diseases
Rakyan, V. K., Down, T. A., Balding, D. J., & Beck, S. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3000 · Cited by 1,288
A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes
MacArthur, D. G., Balasubramanian, S., Frankish, A., Huang, N., Morris, J., Walter, K., Jostins, L., Habegger, L., Pickrell, J. K., Montgomery, S. B., et al. (2012) · Science · doi:10.1126/science.1215040 · Cited by 1,272
Cancer epigenetics reaches mainstream oncology
Rodríguez‐Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,253
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,239
Proteomics by Mass Spectrometry: Approaches, Advances, and Applications
Yates, J. R., Ruse, C. I., & Nakorchevsky, A. (2009) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-061008-124934 · Cited by 1,078
Splicing in disease: disruption of the splicing code and the decoding machinery
Wang, G., & Cooper, T. A. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2164 · Cited by 1,077
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,073
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., der Zee, A. H. M., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,020
Human metabolic individuality in biomedical and pharmaceutical research
CARDIoGRAM, Suhre, K., Shin, S.-Y., Petersen, A.-K., Mohney, R. P., Meredith, D., Wägele, B., Altmaier, E., Deloukas, P., Erdmann, J., et al. (2011) · Nature · doi:10.1038/nature10354 · Cited by 1,017
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J., Kasperavičiūtė, D., Carrington, M. N., Sills, G. J., Marson, A. G., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 936
Gastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3143 · Cited by 891
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878
Pharmaco-metabonomic phenotyping and personalized drug treatment
Andrew Clayton, T., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le Net, J.-L., Baker, D., Walley, R. J., et al. (2006) · Nature · doi:10.1038/nature04648 · Cited by 824
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 822
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker-Neblett, K. L., Spreen, W. R., Lai, E., Davies, K., Handley, A. R., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 808
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 803
MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S. K., Ambs, S., Chen, Y., Meltzer, P. S., Croce, C. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901282 · Cited by 801
Transcriptome genetics using second generation sequencing in a Caucasian population
Montgomery, S. B., Sammeth, M., Gutierrez-Arcelus, M., Lach, R. P., Ingle, C., Nisbett, J., Guigo, R., & Dermitzakis, E. T. (2010) · Nature · doi:10.1038/nature08903 · Cited by 797
Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, P., Lin, J., Lu, C., Ong, C.-T., Hsieh, P. F., Yang, C., Tai, C., Wu, S., Lu, C., Hsu, Y., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009717 · Cited by 710
Metabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah‐Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 685
Quantitative, High-Resolution Proteomics for Data-Driven Systems Biology
Cox, J., & Mann, M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061308-093216 · Cited by 685
Clinical assessment incorporating a personal genome
Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., Dudley, J. T., Ormond, K. E., Pavlovic, A., Morgan, A. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60452-7 · Cited by 674
Clinical application of pharmacogenetics
Spear, B. B., Heath-Chiozzi, M. E., & Huff, J. B. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01986-4 · Cited by 653
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
Johnson, J. A., Gong, L., Whirl‐Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T. M., Pirmohamed, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.185 · Cited by 645
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Takeuchi, F., McGinnis, R. E., Bourgeois, S., Barnes, C. P., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W. M., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000433 · Cited by 639
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 639
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Sundaram, S. K., Sam, L. T., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 638
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
de Haar-Holleman, A., Cheok, M. H.-C., den Boer, M. L., Yang, W., Veerman, A. J. P., Kazemier, K. M., Pei, D., Cheng, C., Pui, C., Relling, M. V., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033513 · Cited by 629
Genomics and Drug Response
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 620
Options and considerations when selecting a quantitative proteomics strategy
Domon, B., & Aebersold, R. H. (2010) · Nature Biotechnology · doi:10.1038/nbt.1661 · Cited by 616
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C.-H., Yee, S. W., Stein, C. M., Whirl‐Carrillo, M., Evans, W. E., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.320 · Cited by 573
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R. E., Rane, A., & Deloukas, P. (2008) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 548
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population
Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq537 · Cited by 518
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Integrative analysis of the cancer transcriptome
Rhodes, D. R., & Chinnaiyan, A. M. (2005) · Nature Genetics · doi:10.1038/ng1570 · Cited by 494
Human Genome Sequencing in Health and Disease
Gonzaga-Jauregui, C. G., Lupski, J. R., & Gibbs, R. A. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-051010-162644 · Cited by 491
Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time
Berg, J. S., Khoury, M. J., & Evans, J. P. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e318220aaba · Cited by 489
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 485
Cancer epigenomics: beyond genomics
Sandoval, J., & Esteller, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.008 · Cited by 485
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134247 · Cited by 481
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group (2010) · Nature Genetics · doi:10.1038/ng.735 · Cited by 452
Implications of the exposome for exposure science
Rappaport, S. M. (2010) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/jes.2010.50 · Cited by 450
Genomic Medicine — An Updated Primer
Feero, W. G., Guttmacher, A. E., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0907175 · Cited by 445
High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients
Saag, M. S., Balu, R. B., Phillips, E. J., Brachman, P. S., Martorell, C. T., Burman, W. J., Stancil, B. S., Mosteller, M., Brothers, C. H., Wannamaker, P. G., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 427
Mass Spectrometry–Based Proteomics and Network Biology
Bensimon, A., Heck, A. J. R., & Aebersold, R. H. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072909-100424 · Cited by 421
A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance
Mishra, P. J., Humeniuk, R., Mishra, P. J., Longo-Sorbello, G. S. A., Banerjee, D., & Bertino, J. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706217104 · Cited by 417
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Meyer, U. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1428 · Cited by 414
Self-citation
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia
Klinakis, A., Lobry, C., Abdel-Wahab, O. I., Oh, P., Haeno, H., Buonamici, S., de Walle, I. V., Cathelin, S., Trimarchi, T., Araldi, E., et al. (2011) · Nature · doi:10.1038/nature09999 · Cited by 400
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 369
Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4156 · Cited by 353
Molecular Staging for Survival Prediction of Colorectal Cancer Patients
Eschrich, S. A., Yang, I. V., Bloom, G., Kwong, K. Y., Boulware, D. C., Cantor, A. B., Coppola, D., Kruhøffer, M., Aaltonen, L. A., Orntoft, T. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.695 · Cited by 344
Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer
Cronin, M. T., Sangli, C., Liu, M., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Clark-Langone, K. M., & Watson, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076497 · Cited by 343
Warfarin Genotyping Reduces Hospitalization Rates
Epstein, R. S., Moyer, T. P., Aubert, R. E., O’Kane, D. J., Xia, F., Verbrugge, R. R., Gage, B. F., & Teagarden, J. R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.009 · Cited by 336
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing
Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D., Whirl‐Carrillo, M., Caudle, K. E., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.103 · Cited by 334
Robust Replication of Genotype-Phenotype Associations across Multiple Diseases in an Electronic Medical Record
Ritchie, M. D., Denny, J. C., Crawford, D. C., Ramirez, A. H., Weiner, J., Pulley, J. M., Basford, M., Brown-Gentry, K. D., Balser, J. R., Masys, D. R., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.03.003 · Cited by 322
The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care
Topol, E. J. (2011) · Thammasat University Digital Collections · Cited by 306
Spectroscopic and Statistical Techniques for Information Recovery in Metabonomics and Metabolomics
Lindon, J. C., & Nicholson, J. K. (2008) · Annual Review of Analytical Chemistry · doi:10.1146/annurev.anchem.1.031207.113026 · Cited by 300
Pharmacogenomics: Challenges and Opportunities
Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00007 · Cited by 293
Challenges and Opportunities of Metabolomics
Johnson, C. H., & Gonzalez, F. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24002 · Cited by 287
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate dispositionPreprint
Ramsey, L. B., Bruun, G. H., Yang, W., Treviño, L. R., Vattathil, S., Scheet, P. A., Cheng, C., Rosner, G. L., Giacomini, K. M., Fan, Y., et al. (2011) · Genome Research · doi:10.1101/gr.129668.111 · Cited by 266
Genome-wide association studies in pharmacogenomics
Daly, A. K. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2751 · Cited by 264
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E. G., Dolan, M. E., Ramı́rez, J., Relling, M. V., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 264
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
Pegram, M. D., Pauletti, G. M., & Slamon, D. J. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111117877 · Cited by 263
Cancer biomarkers: selecting the right drug for the right patient
Kelloff, G. J., & Sigman, C. C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3651 · Cited by 256
Metabonomic, transcriptomic, and genomic variation of a population cohort
Inouye, M., Kettunen, J., Soininen, P., Silander, K., Ripatti, S., Kumpula, L. S., Hämäläinen, E., Jousilahti, P., Kangas, A. J., Männistö, S., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.93 · Cited by 250
Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care
Kim, J. A. (2013) · Healthcare Informatics Research · doi:10.4258/hir.2013.19.3.229 · Cited by 250
Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C
Dill, M. T., Duong, F. H. T., Vogt, J. E., Bibert, S., Bochud, P., Terracciano, L., Papassotiropoulos, A., Röth, V., & Heim, M. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.11.039 · Cited by 250
The $1,000 genome, the $100,000 analysis?
Mardis, E. R. (2010) · Genome Medicine · doi:10.1186/gm205 · Cited by 249
A genome-wide association study of metabolic traits in human urine
Suhre, K., Wallaschofski, H., Raffler, J., Friedrich, N., Haring, R., Michael, K., Wasner, C., Krebs, A., Kronenberg, F., Chang, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.837 · Cited by 246
Systems Biology: An Approach
Kohl, P. K., Crampin, E. J., Quinn, T. A., & Noble, D. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.92 · Cited by 242
microRNA: A Master Regulator of Cellular Processes for Bioengineering Systems
Sun, W., Li, Y.-S. J., Huang, H., Shyy, J. Y.-J., & Chien, S. (2010) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070909-105314 · Cited by 242
Emergency Hospitalization for Adverse Drug Events in Older Americans
Budnitz, D. S., Lovegrove, M. C., Shehab, N., & Richards, C. L. (2012) · Survey of Anesthesiology · doi:10.1097/01.sa.0000412401.21757.36 · Cited by 234
The study of eQTL variations by RNA-seq: from SNPs to phenotypes
Majewski, J., & Pastinen, T. (2011) · Trends in Genetics · doi:10.1016/j.tig.2010.10.006 · Cited by 232
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
Anderson, J. L., Horne, B. D., Stevens, S. M., Woller, S. C., Samuelson, K. M., Mansfield, J. W., Robinson, M., Barton, S., Brunisholz, K. D., Mower, C. P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.070920 · Cited by 229
Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review
Nair, V. S., Maeda, L. S., & Ioannidis, J. P. A. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs027 · Cited by 220
The Predictive Capacity of Personal Genome Sequencing
Roberts, N. J., Vogelstein, J. T., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003380 · Cited by 216
Personalizing medicine with clinical pharmacogenetics
Scott, S. A. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e318238b38c · Cited by 211
Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study
Dyrskjøt, L., Zieger, K., Real, F. X., Malats, N., Carrato, A., Hurst, C. D., Kotwal, S. A., Knowles, M. A., Malmström, P., de la Torre, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2940 · Cited by 206
A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Eissing, T. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00004 · Cited by 204
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
Martin, M. A., Klein, T. E., Dong, B. J., Pirmohamed, M., Haas, D. W., & Kroetz, D. L. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.355 · Cited by 203
Tamoxifen: Catalyst for the change to targeted therapy
Jordan, V. C. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.002 · Cited by 202
Diseases as network perturbations
del Sol, A., Balling, R., Hood, L., & Galas, D. J. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.07.010 · Cited by 184
The SNP Consortium website: past, present and future
Þórisson, G. Á. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg052 · Cited by 184
Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics-Informed Pharmacogenomics
Ji, Y., Hebbring, S. J., Zhu, H., Jenkins, G. D., Biernacka, J. M., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D. J., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.250 · Cited by 163
A vision and strategy for the virtual physiological human in 2010 and beyond
Hunter, P. J., Coveney, P. V., de Bono, B., Díaz‐Zuccarini, V., Fenner, J. W., Frangi, A. F., Harris, P. J. F., Hose, R., Kohl, P. K., Lawford, P. V., et al. (2010) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2010.0048 · Cited by 160
Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans
Winnike, J., Li, Z., Wright, F. A., Macdonald, J. M., O’Connell, T. M., & Watkins, P. B. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.240 · Cited by 160
Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
Blay, J., & von Mehren, M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.016 · Cited by 159
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
Mook, S., Schmidt, M. K., Weigelt, B., Kreike, B., Eekhout, I., van de Vijver, M. J., Glas, A. M., Floore, A. N., Rutgers, E. J. T., & Veer, L. V. ‘. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp388 · Cited by 154
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
Schaeffeler, E., Hellerbrand, C., Nies, A. T., Winter, S., Kruck, S., Hofmann, U., van der Kuip, H., Zanger, U. M., Koepsell, H., & Schwab, M. G. (2011) · Genome Medicine · doi:10.1186/gm298 · Cited by 149
Self-citation
Circumventing Resistance to Kinase-Inhibitor Therapy
Druker, B. J. (2006) · New England Journal of Medicine · doi:10.1056/nejme068073 · Cited by 149
A genome-wide association study of acenocoumarol maintenance dosage
Teichert, M., Eijgelsheim, M., Rivadeneira, F., Uitterlinden, A. G., van Schaik, R. H. N., Albert Hofman, D., Smet, P. A. G. M. D., van Gelder, T., Visser, L. E., & Stricker, B. H. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp309 · Cited by 148
Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence
Dewey, F. E., Chen, R., Cordero, S. P., Ormond, K. E., Caleshu, C. A., Karczewski, K. J., Whirl‐Carrillo, M., Wheeler, M. T., Dudley, J. T., Byrnes, J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002280 · Cited by 141
Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study
Willmann, S., Edginton, A. N., Coboeken, K., Ahr, G., & Lippert, J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.151 · Cited by 138
Genetic association studies in drug-induced liver injury
Daly, A. K., & Day, C. P. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.605790 · Cited by 136
Genetic Warfarin Dosing
Finkelman, B. S., Gage, B. F., Johnson, J. A., Brensinger, C. M., & Kimmel, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.08.643 · Cited by 132
MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response
Rukov, J. L., & Shomron, N. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.04.003 · Cited by 126
The Cardiac Physiome: perspectives for the future
Bassingthwaighte, J. B., Hunter, P. J., & Noble, D. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2008.044099 · Cited by 124
Rare and Common Regulatory Variation in Population-Scale Sequenced Human Genomes
Montgomery, S. B., Lappalainen, T., Gutiérrez‐Arcelus, M., & Dermitzakis, E. T. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002144 · Cited by 108
Pharmacogenetics of Drug Hypersensitivity
Phillips, E. J., & Mallal, S. A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.77 · Cited by 108
Perspectives on the development of imatinib and the future of cancer research
Druker, B. J. (2009) · Nature Medicine · doi:10.1038/nm1009-1149 · Cited by 107
Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
Pharmacogenomic biomarkers: new tools in current and future drug therapy
Sim, S. C., & Ingelman‐Sundberg, M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.008 · Cited by 106
Pharmacogenetics: past, present and future
Pirmohamed, M. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.006 · Cited by 105
Pharmacogenetics and human genetic polymorphisms
Daly, A. K. (2010) · Biochemical Journal · doi:10.1042/bj20100522 · Cited by 105
Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions
Daly, A. K. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134743 · Cited by 105
The virtual liver: a multidisciplinary, multilevel challenge for systems biology
Holzhütter, H., Drasdo, D., Preußer, T., Lippert, J., & HENNEY, A. M. (2012) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1158 · Cited by 104
Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record
Delaney, J. T., Ramirez, A. H., Bowton, E., Pulley, J. M., Basford, M., Schildcrout, J. S., Shi, Y., Zink, R., Oetjens, M. T., Xu, H., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.221 · Cited by 99
Predicting Warfarin Dosage in European–Americans and African–Americans using DNA Samples Linked to an Electronic Health Record
Ramirez, A. H., Shi, Y., Schildcrout, J. S., Delaney, J. T., Xu, H., Oetjens, M. T., Zuvich, R. L., Basford, M., Bowton, E., Jiang, M., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.164 · Cited by 95
Maraviroc
Perry, C. M. (2010) · Drugs · doi:10.2165/11203940-000000000-00000 · Cited by 93
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
Gong, I. Y., Tirona, R. G., Schwarz, U. I., Crown, N., Dresser, G. K., LaRue, S., Langlois, N., Lazo‐Langner, A., Zou, G., Roden, D. M., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345173 · Cited by 93
Old Versus New Oral Anticoagulants: Focus on Pharmacology
Fareed, J., Thethi, I., & Hoppensteadt, D. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134633 · Cited by 90
Personal medicine—the new banking crisis
Scott, C. T., Caulfield, T., Borgelt, E., & Illes, J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2116 · Cited by 85
A systems biology approach to understanding atherosclerosis
Ramsey, S. A., Gold, E. S., & Aderem, A. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000063 · Cited by 85
Clopidogrel: A Case for Indication-Specific Pharmacogenetics
Johnson, J. A., Roden, D. M., Lesko, L. J., Ashley, E. A., Klein, T. E., & Shuldiner, A. R. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.21 · Cited by 82
Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape
Pal, S. K., Figlin, R. A., & Reckamp, K. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0239 · Cited by 81
Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy
Sadée, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., & Johnson, A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.314 · Cited by 79
Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions
Kacevska, M., Ivanov, M., & Ingelman‐Sundberg, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.21 · Cited by 78
Different TBP-associated factors are required for mediating the stimulation of transcriptionin vitroby the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor
Brou, C., Jun, W., Ali, S., Scheer, E., Lang, C., Davidson, I., Chambon, P., & Tora, L. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.1.5 · Cited by 78
Acute Mesenteric Infarction Associated with Atrial Fibrillation
Wang, J., & Chang, S. (2011) · New England Journal of Medicine · doi:10.1056/nejmicm1001885 · Cited by 77
Fulvestrant
Croxtall, J. D., & McKeage, K. (2011) · Drugs · doi:10.2165/11204810-000000000-00000 · Cited by 74
A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Kim, M., Huang, S. M., Meyer, U., Rahman, A., & Lesko, L. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008328098 · Cited by 73
Self-citation
Dasatinib
McCormack, P. L., & Keam, S. J. (2011) · Drugs · doi:10.2165/11207580-000000000-00000 · Cited by 68
The Application of Metabonomics to Predict Drug-Induced Liver Injury
O’Connell, T. M., & Watkins, P. B. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.151 · Cited by 68
Advancing Cell Biology Through Proteomics in Space and Time (PROSPECTS)
Lamond, A. I., Uhlén, M., Horning, S. R., Makarov, A., Robinson, C. V., Serrano, L. G., Hartl, F. U., Baumeister, W. P., Werenskiold, A. K., Andersen, J., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.017731 · Cited by 67
The Systems Biology Approach to Drug Development: Application to Toxicity Assessment of Cardiac Drugs
Rodríguez, B., Burrage, K., Gavaghan, D. J., Grau, V., Kohl, P. K., & Noble, D. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.95 · Cited by 64
Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy
Nicholson, J., Everett, J., & Lindon, J. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.646987 · Cited by 64
PharmGKB summary
McDonagh, E. M., Thorn, C. F., Bautista, J. M., Youngster, I., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834eb313 · Cited by 64
Cetuximab in the treatment of patients with colorectal cancer
Garrett, C. R., & Eng, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582464 · Cited by 60
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese
Kiyotani, K., Mushiroda, T., Tsunoda, T., Morizono, T., Hosono, N., Kubo, M., Tanigawara, Y., Imamura, C. K., Flockhart, D. A., Aki, F., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr597 · Cited by 59
Pharmacogenomics: Application to the Management of Cardiovascular Disease
Johnson, J. A., Cavallari, L. H., Beitelshees, A. L., Lewis, J. P., Shuldiner, A. R., & Roden, D. M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.179 · Cited by 58
Electronic Medical Records as a Tool in Clinical Pharmacology: Opportunities and Challenges
Roden, D. M., Xu, H., Denny, J. C., & Wilke, R. A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.42 · Cited by 51
mRNA Transcript Diversity Creates New Opportunities for Pharmacological Intervention
Barrie, E. S., Smith, R. M., Sanford, J. C., & Sadée, W. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076604 · Cited by 49
The emerging role of microRNAs in drug responses.
Zhang, W., & Dolan, M. E. (2010) · PubMed · Cited by 48
Crizotinib
Curran, M. P. (2011) · Drugs · doi:10.2165/11207680-000000000-00000 · Cited by 47
Cancer biomarkers: surviving the journey from bench to bedside.
Rhea, J. M., & Molinaro, R. J. (2011) · PubMed · Cited by 46
Human genome: Genomes by the thousand
(2010) · Nature · doi:10.1038/4671026a · Cited by 46
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes
Teichert, M., Eijgelsheim, M., Uitterlinden, A. G., Buhre, P. N., Albert Hofman, D., Smet, P. A. G. M. D., Visser, L. E., & Stricker, B. H. C. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834154fb · Cited by 44
Omics and therapy – A basis for precision medicine
Garay, J. P., & Gray, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.009 · Cited by 42
Exemestane
Deeks, E. D., & Scott, L. J. (2009) · Drugs · doi:10.2165/00003495-200969070-00007 · Cited by 41
Genome-wide association study of serious blistering skin rash caused by drugs
Shen, Y., Nicoletti, P., Floratos, A., Pirmohamed, M., Molokhia, M., Geppetti, P., Benemei, S., Giomi, B., Schena, D., Vultaggio, A., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.84 · Cited by 37
The limits of genome-wide methods for pharmacogenomic testing
Gamazon, E. R., Skol, A. D., & Perera, M. A. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328350ca5f · Cited by 35
Evaluating Pharmacokinetic and Pharmacodynamic Interactions with Computational Models in Supporting Cumulative Risk Assessment
Tan, Y., M.A., H. J. C. I., Campbell, J. L., & Andersen, M. E. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8051613 · Cited by 33
Role of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants
Koturbash, I., Beland, F. A., & Pogribny, I. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.673587 · Cited by 30
Using Metabolomics to Monitor Anticancer Drugs
Chung, Y., & Griffiths, J. R. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_089 · Cited by 30
Personalized Medicine: A Personal View
Meyer, U. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.238 · Cited by 26
Self-citation
An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
Barnadas, A., García‐Estévez, L., Lluch-Hernández, A., Rodríguez-Lescure, Á., Rodriguez-Sanchez, C., & Sánchez‐Rovira, P. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0075-4 · Cited by 22
Genetic determinants of response to cardiovascular drugs
Wells, Q. S., Delaney, J. T., & Roden, D. M. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32835220e3 · Cited by 20
Building a Foundation for the Human Proteome: The Role of the Human Proteome Organization
Hanash, S. (2004) · Journal of Proteome Research · doi:10.1021/pr034126h · Cited by 18
Panitumumab: A Summary of Clinical Development in Colorectal Cancer and Future Directions
Argilés, G., Dienstmann, R., Élez, E., & Tabernero, J. M. (2012) · Future Oncology · doi:10.2217/fon.12.20 · Cited by 17
Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2020035 · Cited by 9

Research works printed but not linked: 6

Natl. Res. Counc., 2011, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
Rappaport SM, 2011, Nucleic Acids Res., 21, 5
10.1038/nature10166 · DOI · Paper page
Zhang W, 2010, Curr. Opin. Mol. Ther., 12, 695
Rhea JM, 2011, MLO Med. Lab. Obs., 43, 10
Blay J-Y, 2011, Semin. Oncol., 38, S3

Sorted by citations

Analytical Methods in Untargeted Metabolomics: State of the Art in 2015
Alonso, A., Marsal, S., & Julià, A. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00023 · Cited by 727
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars
Li, M., Tian, S., Jin, L. G., Zhou, G., Li, Y., Zhang, Y., Wang, T., Yeung, C. K. L., Chen, L., Ma, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2811 · Cited by 560
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z. M., Zhou, J., & Chen, S. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 415
Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 338
Self-citation
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M. G., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 313
Self-citation

See all 157

Authors: Meyer, U. A., Zanger, U. M., & Schwab, M.
Affiliations: University of Basel (CH)
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
Universitätsklinikum Tübingen (DE)
ORCID: Meyer, Urs A.
Zanger, Ulrich M.
Schwab, Matthias
Venue: Annual Review of Pharmacology and Toxicology
Publisher: Annual Reviews
Published: 2013-01-06
Volume: 53
Issue: 1
Pages: 475-502
ISSN: 0362-1642 (ISSN-L)
1545-4304
DOI: 10.1146/annurev-pharmtox-010510-100502
OpenAlex: W2098156682
Cited by: 157
References: 196
Citations by year: 2026: 3 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 15 · 2016: 12 · 2015: 17 · 2014: 17 · 2013: 14
FWCI: 1.58
Type: journal article
Language: en
Open access: closed
Locations: The Annual Review of Pharmacology and Toxicology (publishedVersion)
PubMed (publishedVersion)
Funders: Robert Bosch Stiftung
Bundesministerium für Bildung und Forschung
National Institutes of Health
National Human Genome Research Institute
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords: omics technologies, drug response, personalized medicine, pharmacogenomics, drug selection, drug dosing, treatment response variability, clinical outcomes, precision medicine
MeSH terms: Animals, Humans, Pharmacogenetics, Genomics, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Omics and Drug Response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks